Lipigon Pharmaceuticals AB (publ) (STO:LPGO)

Market Cap	3.64M -84.8%
Revenue (ttm)	1.32M -85.3%
Net Income	-35.97M
EPS	-0.14
Shares Out	605.93M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,776,979
Average Volume	5,981,181
Open	0.0056
Previous Close	0.0056
Day's Range	0.0044 - 0.0078
52-Week Range	0.0040 - 0.3695
Beta	0.79
RSI	34.88
Earnings Date	Feb 20, 2026

About STO:LPGO

Lipigon Pharmaceuticals AB (publ), a clinical-stage pharmaceutical company, develops drugs for lipid related diseases in Sweden. Its product pipeline consists of Lipisense project, which is in phase II for the treatment of severe hypertriglyceridemia disease; Dyslipidemia project, which is in preclinical trial to treat cardiovascular disease and severe hypertriglyceridemia; and CAP project, which is in preclinical trial to treat and prevent lung injury associated with community-acquired pneumonia. The company has a license agreement with Leader...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 7
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: LPGO

Financial Performance

In 2024, STO:LPGO's revenue was 10.29 million, a decrease of -37.30% compared to the previous year's 16.41 million. Losses were -25.26 million, 108.3% more than in 2023.